“We believe BOOST Pharma’s innovative approach to treating osteogenesis imperfecta has enormous potential to deliver not only clinical impact for patients but also durable value creation. We look forward to working together to reach new milestones,” says Johan Kördel, Managing Partner at Sound Bioventures.

Support continued clinical development

The financing will support continued clinical development of BT-101, BOOST Pharma’s stem cell-based therapy for osteogenesis imperfecta (OI), also known as brittle bone disease.

BT-101 is designed for early intervention, administered to infants to address the underlying cause of OI and reduce fracture frequency in affected children. With this new investment, BOOST Pharma aims to accelerate clinical development and move closer to delivering the first disease-modifying therapy for OI, a devastating genetic condition with no currently approved treatments.

“We are honored to welcome Sound Bioventures to our syndicate—a collaborative, hands-on investor group that shares our vision of transforming care for children living with rare skeletal diseases,” says Ingelise Saunders, Chair of BOOST Pharma. “Their commitment strengthens BOOST Pharma’s position as a leader in cell therapy for genetic bone disorders and enables continued progress of BT-101 towards the clinic.”